Karyopharm Therapeutics

30-DAY NOTICE FOR NEW PRESCRIPTION DRUG PURSUANT TO 18 V.S.A. § 4637(C)

TO: Office of the Attorney General of Vermont
AGO.highcostprescriptiondrugs@vermont.gov

FROM: Karyopharm Therapeutics Inc.

DATE: August 2, 2019

Pursuant to 18 V.S.A. § 4637(b), on July 3, 2019, Karyopharm Therapeutics Inc. ("Karyopharm") submitted a notice of the introduction of a new prescription drug for the following (collectively, the "Product"):

Product	NDC
XPOVIO™ (selinexor) 60mg (12 Tablets)	72237-101-01
XPOVIO™ (selinexor) 80mg (16 Tablets)	72237-101-02
XPOVIO™ (selinexor) 160mg (32 Tablets)	72237-101-04
XPOVIO™ (selinexor) 100mg (20 Tablets)	72237-101-05

As required by 18 V.S.A. § 4637(c), Karyopharm now provides the following additional information regarding the Product:

US and International Marketing and Pricing Plans Used in Launch: The US and international marketing and pricing plans used in the launch of the Product are not in the public domain and are confidential and proprietary information of Karyopharm, therefore Karyopharm declines to provide this information in accordance with 18 V.S.A. § 4637(d).

Estimated Volume of Patients: The estimated volume of patients who may be prescribed the Product is not in the public domain and is confidential and proprietary information of Karyopharm, therefore Karyopharm declines to provide this information in accordance with 18 V.S.A. § 4637(d).

Breakthrough Therapy Designation or Priority Review: The Product was granted priority review by the FDA. The Product did not receive a breakthrough therapy designation from the FDA.

Date and Price of Acquisition: The Product was not the result of an acquisition.

85 Wells Avenue
Suite 210
Newton, MA 02459

www.karyopharm.com